- Home
- SAVA vs VERI Comparison
SAVA vs VERI Comparison
Compare SAVA & VERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- VERI
- Stock Information
- Founded
- SAVA 1998
- VERI 2014
- Country
- SAVA United States
- VERI United States
- Employees
- SAVA N/A
- VERI N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- VERI EDP Services
- Sector
- SAVA Health Care
- VERI Technology
- Exchange
- SAVA Nasdaq
- VERI Nasdaq
- Market Cap
- SAVA 134.2M
- VERI 112.7M
- IPO Year
- SAVA N/A
- VERI 2017
- Fundamental
- Price
- SAVA $2.59
- VERI $2.43
- Analyst Decision
- SAVA Buy
- VERI Hold
- Analyst Count
- SAVA 3
- VERI 1
- Target Price
- SAVA $111.50
- VERI $2.25
- AVG Volume (30 Days)
- SAVA 12.4M
- VERI 792.9K
- Earning Date
- SAVA 11-07-2024
- VERI 11-12-2024
- Dividend Yield
- SAVA N/A
- VERI N/A
- EPS Growth
- SAVA N/A
- VERI N/A
- EPS
- SAVA N/A
- VERI N/A
- Revenue
- SAVA N/A
- VERI $124,881,000.00
- Revenue This Year
- SAVA N/A
- VERI $10.27
- Revenue Next Year
- SAVA N/A
- VERI $2.47
- P/E Ratio
- SAVA N/A
- VERI N/A
- Revenue Growth
- SAVA N/A
- VERI 6.94
- 52 Week Low
- SAVA $2.55
- VERI $1.48
- 52 Week High
- SAVA $42.20
- VERI $7.76
- Technical
- Relative Strength Index (RSI)
- SAVA 23.06
- VERI 37.64
- Support Level
- SAVA $2.78
- VERI $2.32
- Resistance Level
- SAVA $3.28
- VERI $2.67
- Average True Range (ATR)
- SAVA 0.24
- VERI 0.19
- MACD
- SAVA 0.40
- VERI 0.01
- Stochastic Oscillator
- SAVA 4.73
- VERI 19.84
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel and India.